ClinicalTrials.gg
CompletedNCT01260922Updated Feb 21, 2011Results posted

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.

A Phase 1 interventional study of Donepezil Hydrochloride and Aricept® in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-02-21.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study investigated the relative bioavailability (rate and extent of absorption) of Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg by Teva Pharmaceuticals, USA with that of Aricept® Orally Disintegrating Tablets, Manufactured and Marketed by Eisai Inc., following a single oral dose (1 x 10 mg orally disintegrating tablet) in healthy adult subjects administered under fasting conditions.

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Screening Demographics: All volunteers for this study will be healthy men and women 18 years of age or older at the time of dosing. The weight range will not exceed + 20% for height and body frame as per Desirable Weights for Adults-1983 Metropolitan Height and Weight Table.
  • Screening Procedures: Each volunteer will complete the screening process within 28 days prior to Period I dosing. Consent documents for both the screening evaluation and antibody determination will be reviewed, discussed, and signed by each potential participant before full implementation of screening procedures.
  • If female and:

    • of , is practicing an acceptable method of for the duration of the study as judged by the investigator(s); or
    • is for at least 1 year; or
    • is surgically sterile.

Exclusion criteria

Exclusion Criteria:

  • Volunteers with a recent history of drug or alcohol addiction or abuse.
  • Volunteers with the presence of a disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the clinical investigators).
  • Volunteers whose clinical laboratory test values are outside the accepted reference range and when confirmed on reexamination are deemed to be clinically significant.
  • Volunteers demonstrating a reactive screen for surface antigen, antibody, or antibody.
  • Volunteers demonstrating a positive drug abuse screen when screened for this study.
  • Female volunteers demonstrating a positive pregnancy screen.
  • Female volunteers who are currently breastfeeding.
  • Volunteers with a history of allergic response(s) to donepezil or related drugs.
  • Volunteers with a history of clinically significant allergies including drug allergies.
  • Volunteers with a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the clinical investigators).
  • Volunteers who currently use tobacco products.
  • Volunteers who have taken any drug known to induce or inhibit hepatic drug metabolism in the 28 days prior to Period I dosing.
  • Volunteers who report donating greater than 150 mL of blood within the 28 days prior to Period I dosing.
  • Volunteers who have donated plasma within 14 days prior to Period I dosing.
  • Volunteers who report receiving any drug within 28 days prior to Period I dosing.
  • Volunteers who report taking any systemic prescription medication in the 14 days prior to Period I dosing.
  • Female volunteers who report the use of oral or injectable contraceptives.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Investigational Test Product

    Donepezil Hydrochloride 10 mg Orally Disintegrating Tablets

    Drug: Donepezil Hydrochloride

  • Active comparator
    Reference Listed Drug

    Aricept® 10 mg Orally Disintegrating Tablets

    Drug: Aricept®

Interventions

  • 10 mg Orally Disintegrating Tablet

  • 10 mg Orally Disintegrating Tablet

    Also known as: Donepezil Hydrochloride (generic name)

06

What researchers measure

Primary outcomes

  1. Cmax of Donepezil.

    Bioequivalence based on Donepezil Cmax (maximum observed concentration of drug substance in plasma).

    Time frame: Blood samples collected over a 72 hour period.

  2. AUC0-t of Donepezil.

    Bioequivalence based on Donepezil AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).

    Time frame: Blood samples collected over a 72 hour period.

07

Results

Posted Feb 21, 2011

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneDonepezil Hydrochloride (Test) FirstAricept® (Reference) First
Started1313
Completed1312
Not completed01
Withdrew: Withdrawal by subject01
Washout of 28 Days
Participant flow — Washout of 28 Days
MilestoneDonepezil Hydrochloride (Test) FirstAricept® (Reference) First
Started1312
Completed910
Not completed42
Withdrew: Withdrawal by subject42
Second Intervention
Participant flow — Second Intervention
MilestoneDonepezil Hydrochloride (Test) FirstAricept® (Reference) First
Started910
Completed98
Not completed02
Withdrew: Emesis02

Outcome measures

PrimaryCmax of Donepezil.

Bioequivalence based on Donepezil Cmax (maximum observed concentration of drug substance in plasma).

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · ng/mL
Cmax of Donepezil.
ng/mLDonepezil Hydrochloride (Test)Aricept® (Reference)
Cmax of Donepezil.17800.27 ± 4515.3617280.23 ± 4032.57
Statistical analysis
  • Donepezil Hydrochloride (Test) vs Aricept® (Reference) · Ratio of the t/r geometric mean x 100: 102.16 · 90% CI 97.07 to 107.51Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.
PrimaryAUC0-t of Donepezil.

Bioequivalence based on Donepezil AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).

Time frame:
Blood samples collected over a 72 hour period.
Reported as:
Mean · ng*h/mL
AUC0-t of Donepezil.
ng*h/mLDonepezil Hydrochloride (Test)Aricept® (Reference)
AUC0-t of Donepezil.466307.49 ± 85094.55490716.21 ± 86199.11
Statistical analysis
  • Donepezil Hydrochloride (Test) vs Aricept® (Reference) · Slope: 94.75 · 90% CI 92.11 to 97.46Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference (R) and test (T) product fall within the interval of 80-125%.

Adverse events

Collected over Adverse event data was collected over the course of the study, which was approximately 8 weeks in duration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Donepezil Hydrochloride (Test) First—0/26 (0%)10/26 (38.5%)
Aricept® (Reference) First—0/26 (0%)6/26 (23.1%)
Most frequent other events
Most frequent other events
EventDonepezil Hydrochloride (Test) FirstAricept® (Reference) First
NauseaGeneral disorders5/264/26
VomitingGeneral disorders5/263/26
HeadacheGeneral disorders3/261/26
DizzinessGeneral disorders0/262/26
Abnormal DreamsGeneral disorders2/260/26
Feeling HotGeneral disorders2/260/26

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Donepezil Hydrochloride (Test) FirstAricept® (Reference) FirstTotal
<=18 years000
Between 18 and 65 years131326
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Donepezil Hydrochloride (Test) FirstAricept® (Reference) FirstTotal
Female7916
Male6410
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Donepezil Hydrochloride (Test) FirstAricept® (Reference) FirstTotal
Hispanic101
Caucasian121325
Region of Enrollment
Region of Enrollment(participants)Donepezil Hydrochloride (Test) FirstAricept® (Reference) FirstTotal
United States131326
08

Study locations

1 site
  • PRACS Institute, Ltd.
    East Grand Forks, Minnesota 56721, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of May 2006 and a completion of May 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2010
First posted
Dec 15, 2010
Start
Apr 2006
Primary completionActual
May 2006
CompletionActual
May 2006
Results first posted
Feb 21, 2011
Last update
Feb 21, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01260922
First posted
Dec 15, 2010
Start date
Apr 2006
Primary completion
May 2006
Completion
May 2006
Results posted
Feb 21, 2011
Last update
Feb 21, 2011

Study contacts

James D Carlson, Pharm.D.
principal investigator · PRACS Institute, Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion